Hikal Ltd. has announced the successful completion of the Good Manufacturing Practices (GMP) audit conducted by the Brazilian Health Regulatory Agency (ANVISA) at its manufacturing facility located in Jigani, Bengaluru, Karnataka. The audit was carried out between April 14 and April 18, 2025.
In the exchange filing, the company shared, “The company has successfully passed the Brazilian Health Regulatory Agency’s (ANVISA) GMP audit for its manufacturing unit located at Jigani in Bengaluru, Karnataka. The inspection, carried out by ANVISA, Brazil GMP (Good Manufacturing Practices), was for multiple API’s which occurred from April 14th to April 18th, 2025.”
The inspection focused on multiple Active Pharmaceutical Ingredients (APIs) produced at the Jigani site. The facility met all compliance requirements laid out by ANVISA, reaffirming Hikal’s commitment to maintaining high-quality manufacturing standards aligned with international regulatory norms.
